A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

NCT03234036 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: GSK2838232 100 mg tablet
DRUG: GSK2838232 50 mg capsule
DRUG: Ritonavir 100 mg tablets
DRUG: Placebo for GSK2838232 tablets

Sponsor

GlaxoSmithKline